Adjuvant Chemoradiation Following Radical Resection of Pancreatic Ductal Adenocarcinoma, a Prospective Cohort Study
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 400
- 试验地点
- 1
- 主要终点
- Overall Survival
研究概览
简要总结
This is a prospective observation cohort study to evaluate efficacy of different types of adjuvant therapy strategies, including chemoradiotherapy, chemotherapy alone, or no adjuvant treatment, for pancreatic ductal adenocarcinoma patients who received surgical resection of primary cancer.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age between 18 to 90 years.
- •Received surgical resection of primary tumor.
- •Histological diagnosis of pancreatic ductal adenocarcinoma.
- •Signed informed consent.
排除标准
- •1.Active concomitant malignancy (Malignancy other than pancreatic cancer).
研究组 & 干预措施
No adjuvant treatment
Pancreatic cancer patients who received surgery without subsequent adjuvant treatment.
干预措施: Follow-up only (Other)
Adjuvant chemotherapy
Pancreatic cancer patients who received surgery and only adjuvant chemotherapy.
干预措施: Adjuvant chemotherapy (Drug)
Adjuvant chemoradiotherapy
Pancreatic cancer patients who received surgery and only adjuvant chemoradiotherapy.
干预措施: Adjuvant chemoradiotherapy (Radiation)
Adjuvant chemoradiotherapy + adjuvant chemotherapy
Pancreatic cancer patients who received surgery and both adjuvant chemoradiotherapy and chemotherapy.
干预措施: Adjuvant chemoradiotherapy + Adjuvant chemotherapy (Radiation)
结局指标
主要结局
Overall Survival
时间窗: Up to 60 months
Overall survival (OS) was defined as the time interval from the date of surgery to the date of death due to any cause or the date a patient was last known to be alive. Estimated by using the Kaplan-Meier method.
次要结局
- Disease Free Survival(Up to 48 months)